达菲林联合左炔诺孕酮缓释系统对治疗子宫腺肌症患者的效果及安全性分析  

Efficacy and Safety Analysis of Diphereline Combined with Levonorgestrel Sustained Release System in the Treatment of Patients with Uterine Adeno⁃myosis

作　　者：姜梅梅 JIANG Meimei(Department of Gynecology,Nanjing Jiangning Hospital of Traditional Chinese Medicine,Nanjing,Jiangsu Province,211100 China)

机构地区：[1]南京市江宁中医院妇科,江苏南京211100

出　　处：《中外医疗》2024年第6期90-93,共4页China & Foreign Medical Treatment

摘　　要：目的探究达菲林联合左炔诺孕酮缓释系统对治疗子宫腺肌症患者的效果及安全性。方法方便选取2019年6月—2022年12月南京市江宁中医院收治的102例子宫腺肌症患者作为研究对象,所有患者入院后进行编号,并利用红蓝球法随机分为对照组、观察组,各51例。对照组予以左炔诺孕酮缓释系统治疗,观察组在对照组基础上联合达菲林治疗。治疗后,对比两组患者的临床疗效、血清因子水平及安全性。结果观察组的治疗总有效率为96.08%,高于对照组的84.31%,差异有统计学意义(χ^(2)=3.991,P<0.05)。治疗后,两组患者的人附睾蛋白水平比较,差异无统计学意义(P>0.05);观察组的癌抗原199[(38.21±4.12)U/mL]、癌抗原125[(16.57±3.71)U/mL]水平均低于对照组,差异有统计学意义(t=7.119、5.350,P均<0.05);观察组不良事件总发生率(3.92%)低于对照组(17.65%),差异有统计学意义(χ^(2)=4.993,P<0.05)。结论针对子宫腺肌症患者,采取达菲林联合左炔诺孕酮缓释系统治疗有助于进一步提升临床治疗效果,并降低子宫腺肌症相关因子水平,且安全性较高。Objective To explore the efficacy and safety of Dafiline combined with levonorgestrel sustained release system in the treatment of patients with uterine adenomyosis.Methods A total of 102 patients with adenomyosis admit-ted to Nanjing Jiangning Hospital of Traditional Chinese Medicine from June 2019 to December 2022 were conve-niently selected as the study objects.All patients were numbered after admission,and randomly divided into control group and observation group with 51 cases in each group using the red and blue ball method.The control group was treated with levonorgestrel sustained release system,and the observation group was treated with Dafilin on the basis of the control group.After treatment,the clinical efficacy,serum factor levels and safety of the two groups were compared.Results The total effective rate of the observation group was 96.08%,higher than that of the control group(84.31%),and the difference was statistically significant(χ^(2)=3.991,P<0.05).After treatment,there was no significant difference in the level of human epididymis protein 4 between the two groups(P>0.05).The levels of Cancer Antigen 199(38.21±4.12)U/mL and cancer antigen 125(16.57±3.71)U/mL in observation group were lower than those in control group,and the difference was statistically significant(t=7.119,5.350,both P<0.05).The total incidence of adverse events in the observation group(3.92%)was lower than that in the control group(17.65%),and the difference was statistically significant(χ^(2)=4.993,P<0.05).Conclusion For patients with adenomyosis,the combination of Tamiline and levonorg-estrel sustained release system can help to further improve the clinical therapeutic effect and reduce the level of ad-enomyosis related factors,with high safety.

关 键 词：达菲林 左炔诺孕酮缓释系统 子宫腺肌症 血清因子 临床疗效 安全性 

分 类 号：R4[医药卫生—临床医学]